Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova最新文献

{"title":"[Determining the risk of maladaptation using an electroencephalogram to prevent mental strain].","authors":"T V Popova, Y I Koryukalov, O G Kourova","doi":"10.17116/jnevro202412408197","DOIUrl":"https://doi.org/10.17116/jnevro202412408197","url":null,"abstract":"<p><strong>Objective: </strong>To identify criteria for electroencephalogram (EEG) synchronization in patients with post-traumatic stress disorder (PTSD) exhibiting high levels of functional stress and signs of maladaptation.</p><p><strong>Material and methods: </strong>Two groups of male subjects aged 23-38 years were examined: a group of subjects receiving therapy for PTSD at a medical center; and a group of healthy subjects who regularly practiced psychophysical relaxation sessions. EEG, an innovative method for analyzing brain synchronizing currents, and the Spielberger State-Trait Anxiety Inventory were used.</p><p><strong>Results: </strong>Criteria for the formation of patterns of synchronization of neural networks were found in subjects of the therapy group, who have a high level of psychofunctional stress and signs of maladaptation against the background of PTSD in combination with severe anxiety and impaired cognitive abilities.</p><p><strong>Conclusion: </strong>Alpha wave synchronization analysis can be used to more accurately diagnose the level of psychofunctional stress in individuals at risk of developing psychophysical disorders. The results of the work suggest the use of technologies that increase the ability to synchronize brain biocurrents to develop programs for correcting psychophysical status, such as relaxation exercises.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 8","pages":"97-102"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The first experience with the use of divozilimab in the treatment of multiple sclerosis patients in daily clinical practice].","authors":"V M Lebedev, E D Kuzminykh","doi":"10.17116/jnevro202412407295","DOIUrl":"10.17116/jnevro202412407295","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to assess the efficacy and safety of divozilimab in patients who have received post-marketing treatment and participants of clinical trials BCD-132-2 and BCD-132-4 were conducted at the IHB RAS. Additionally, we will present a case report of divozilimab therapy in a patient with highly active multiple sclerosis (MS).</p><p><strong>Material and methods: </strong>The study included 27 patients with MS. We assessed the dynamics of neurological status, magnetic resonance imaging (MRI) findings, and disability level during divozilimab treatment. We also analyzed the incidence and severity of adverse events (AE), including infusion reactions.</p><p><strong>Results: </strong>During treatment with divozilimab, no exacerbations or radiological disease activity were observed after the first six months. Complete clinical remission was achieved in 25 patients. All 12 patients who received the drug as part of post-marketing use met the NEDA-3 criteria, and five of them showed improvement. Most AE were mild, none exceeding grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE). Laboratory parameter changes were also mild and did not exceed I-II grade according to CTCAE. There were no instances of therapy discontinuation due to intolerance.</p><p><strong>Conclusion: </strong>The data from post-registration use of divozilimab confirm the results of clinical trials, showing high efficacy of the drug with a predictable and favorable safety profile.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 7. Vyp. 2","pages":"91-95"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Polymorphic variants in the cluster of genes encoding trace amine receptors and cognitive functioning in patients with schizophrenia spectrum disorders and healthy controls].","authors":"M V Alfimova, V V Plakunova, T V Lezheiko, V E Golimbet","doi":"10.17116/jnevro2024124091122","DOIUrl":"10.17116/jnevro2024124091122","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association of polymorphisms in the <i>TAAR1-9</i> gene cluster on chromosome 6 with cognitive functions in patients with schizophrenia spectrum disorders and healthy controls.</p><p><strong>Material and methods: </strong>Patients with schizophrenia spectrum disorders (<i>n</i>=216) and healthy people without a family history of mental disorders (<i>n</i>=240) completed a battery of cognitive tests, from which individual indices of cognitive functioning were derived. Associations of the cognitive index with 22 polymorphisms in the <i>TAAR</i> genes were assessed using ANCOVA controlling for sex, age, genetic structure of the sample, and polygenic risk scores of schizophrenia and intelligence.</p><p><strong>Results: </strong>An interaction effect between group and genotype on the cognitive index was found at the rs3813355 site in the <i>TAAR5</i> gene (F=6.68; <i>p</i>=0.010; η²_p=0.02). A <i>post hoc</i> analysis revealed genotype-related differences in the patient group. Homozygotes for the common <i>A</i> allele had a milder cognitive deficit than carriers of the minor <i>G</i> allele (<i>t</i>=2.75; <i>p</i>=0.032; Cohen's d=0.38). The effect of genotype on cognitive index remained significant after the inclusion of disease duration and negative symptoms in the model (F=7.99; <i>p</i>=0.005; η²_p=0.04). Of the individual cognitive indicators, associations with genotype were found for working memory and attention (F=8.25; <i>p</i>=0.005; η²p=0.05), cognitive flexibility (F=5.82; <i>p</i>=0.017; η²_p=0.05) and verbal episodic memory (F=6.75; <i>p</i>=0.011; η²_p=0.05).</p><p><strong>Conclusion: </strong>The results are consistent with the assumption of the role of the <i>TAAR5</i> genetic polymorphism in the variability of cognitive deficits in patients with schizophrenia.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 9","pages":"122-128"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Sarcopenia as a non-motor symptom of Parkinson's disease].","authors":"N G Zhukova, M V Matveeva, P E Kazantseva, Iu G Samoilova, A Ya Masenko, O V Gaponova, I A Zhukova","doi":"10.17116/jnevro202412409115","DOIUrl":"10.17116/jnevro202412409115","url":null,"abstract":"<p><p>Sarcopenia is a progressive generalized skeletal muscle disease that is accompanied by an accelerated loss of muscle mass and function, affecting the quality of life and the ability to perform self-care. The prevalence of sarcopenia in the world today ranges from 10 to 25%, which represents a certain danger as it is a prognostic factor for possible injury and increased disability in the elderly population. Sarcopenia often accompanies a large number of different diseases, including neurodegenerative ones, so it is actively studied in this category of patients, for example, as one of the early symptoms of Parkinson's disease (PD). PD and sarcopenia have overlapping pathophysiological mechanisms of muscle fiber loss: inflammation, muscle autophagy, oxidative stress and apoptosis. Loss of muscle mass due to malnutrition is common in PD. According to some studies, the prevalence of sarcopenia in PD varies from 6 to 55.8%; weakness and sarcopenia are more common in patients with PD than in society as a whole, which is associated with an unfavorable course of the disease. The presence of both diseases simultaneously in one patient can impose certain restrictions on the treatment of the patient, worsen his physical and mental condition, which determines the need for early detection of sarcopenia in patients with PD.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 9","pages":"15-22"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical and dynamic features of alcoholism formation in middle-aged and elderly patients with primary organic mental disorders].","authors":"R A Kardashyan, A A Efremov","doi":"10.17116/jnevro202412409173","DOIUrl":"10.17116/jnevro202412409173","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical and dynamic features of the formation of alcohol dependence (AD) in middle-aged and elderly people with primary organic mental disorders (POMD).</p><p><strong>Material and methods: </strong>The study included 83 male patients aged 67.5±7.2 years with POPR, complicated by mid-stage AD, who were divided into 2 groups. The 1st group included 49 (59%) patients, the 2nd - 34 (41%) patients who had symptoms of POPR at 39.2±2.8 and 46.5±2.2 years, respectively, and alcohol withdrawal syndrome (AWS) formed at 53.8±1.2 years and 66.8±0.9 years, accordingly. The study used questionnaires - social interviews, clinical (anamnesis collection), catamnestic, dynamic observation, statistical (parametric and nonparametric) methods.</p><p><strong>Results: </strong>Patients of group 1 began systematic alcohol intake at a younger age (cf. age 46.2±1.2 years), a low-grade course prevailed (53.1%), AWS appeared at an average age of 57.2±1.8 years, was of pronounced severity (21.32±2.48 points), the psychopathological variant dominated. Systematic alcohol intake in patients of the 2nd group began at a later age (58.4±1.4 years), they had a predominant (41.2%) - a moderate course, AWS was formed more often (41.2%) in the elderly (66.2±1.2 years), was of moderate severity (CIWA, 18.81±1.92 points), the cerebral variant prevailed. The average duration of AWS and light intervals in patients of group 1 was longer (<i>p</i><0.05), respectively - 5.5±1.5 days and 23.3±2.8 days.</p><p><strong>Conclusion: </strong>The development of POMD symptoms at a young age may have an impact on the formation of AZ in middle age, a pronounced degree of severity of AWS, a low-grade course, and the appearance of POMD symptoms in middle age - on the later formation of AD, the average severity of the course of AWS, a medium-grade course.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 9","pages":"73-78"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Electric activity of the brain at early and late clinical stages of experimental modeling of Parkinson's disease, an impact of hemantane].","authors":"N A Voronina, I G Kapitsa, V G Kucheryanu, V V Goloborshchova, T A Voronina","doi":"10.17116/jnevro2024124091129","DOIUrl":"10.17116/jnevro2024124091129","url":null,"abstract":"<p><strong>Abstract: </strong>S.</p><p><strong>Objective: </strong>To study an influence of the adamantane derivative hemantane on the electrical activity of the brain structures of mice at the early and late (severe) stages of experimental modeling of Parkinson's disease (PD).</p><p><strong>Material and methods: </strong>For experimental modeling of PD in C57BL/6J mice, 30 male C57BL/6J mice weighing 25-32 g were systemically (intraperitoneally) administered proneurotoxin MPTP in two modes corresponding to different clinical stages of the disease: 1-methyl-4-phenyl-1.2.3.6-tetrahydropyridine (MPTP) at a dose of 12 mg/kg, 4 times and 20 mg/kg, 4 times with an interval of 2 hours, respectively.</p><p><strong>Results: </strong>At the early and late clinical stages of experimental modeling of PD in the brain structures of mice (sensorimotor cortex, substantia nigra, caudate nucleus), EEG desynchronization, an increase in wave amplitude, and an increase in the power spectrum in the range of delta frequencies and beta frequencies are observed at the late symptomatic stage experimental model of PD along with a decrease in electrical activity in the range of 4-12 Hz. Preliminary application of the adamantane derivative hemantane at a dose of 20 mg/kg, both in the early and late clinical stages of PD, prevented an excessive increase in the amplitudes of all groups of waves, normalized theta activity in the range of 4-12 Hz, reduced pathological slowing and dysregulation activity in the ranges delta and beta waves, with the prevalence of these effects in the substantia nigra of the brain of animals.</p><p><strong>Conclusion: </strong>The effect of hemantane is more pronounced at the early clinical stage of experimental modeling of PD than at the later (full-scale) stage.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 9","pages":"129-134"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Studying the possibility of using methods for assessing expressive speech developmental disorders in children 3-6 years old].","authors":"I I Smirnov, E S Popova, O V Serebrovskaya, L A Skipetrova, R A Cheremin, V V Fateeva","doi":"10.17116/jnevro2024124112103","DOIUrl":"https://doi.org/10.17116/jnevro2024124112103","url":null,"abstract":"<p><strong>Objective: </strong>To study the possibility of using methods (DP-3, speech therapy examination, neuropsychological study) to assess expressive speech development disorders in children aged 3 to 6 years inclusive.</p><p><strong>Material and methods: </strong>The study included 60 children with expressive speech disorder aged 3 to 6 years. At the initial stage, linguistic validation of the questionnaire was carried out according to generally accepted recommendations. Two Russian-speaking professional translators in the field of medicine performed a direct translation of the original English-language scale, a reverse translation was carried out by native speakers with medical education. At the final stage of validation, a study of the psychometric indicators of the developed Russian version was carried out.</p><p><strong>Results: </strong>A Russian-language version of DP-3 has been developed with a high level of reliability, internal consistency and sensitivity. The Pearson correlation coefficient in the test-retest DP3 reliability study was 0.8 (<i>p</i><0.0001), which confirms the high level of stability of the scale to deviations. In the study of internal consistency in the domain «communicative development» DP-3, the Cronbach's alpha coefficient was 0.83 (<i>p</i><0.0001), which indicates a high internal consistency for this domain of the Russian version of the DP-3 questionnaire. The values for the domain «communicative development» DP-3 significantly correlated with the results of the speech therapy examination. The values of the DP-3 «communicative development» domain significantly correlated with the indicators of the speech therapy examination.</p><p><strong>Conclusion: </strong>It was demonstrated that the Russian version of the DP-3 questionnaire is a reliable and valid tool for assessing the level of development of speech communication in preschool children (3-6 years old). DP-3 can serve as a reliable tool for quantitative assessment of the dynamics of speech development against the background of therapeutic and correctional measures.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 11. Vyp. 2","pages":"103-109"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Features of fibromyalgia in patients with rheumatoid arthritis].","authors":"N A Melikova, E G Filatova, E S Filatova","doi":"10.17116/jnevro202412402128","DOIUrl":"10.17116/jnevro202412402128","url":null,"abstract":"<p><strong>Objective: </strong>To determine the features of fibromyalgia (FM) in patients with rheumatoid arthritis (RA).</p><p><strong>Material and methods: </strong>Seventy-six patients participated in the study. The patients were divided into 2 groups: RA+FM (<i>n</i>=55), FM (<i>n</i>=21). Anamnesis of life and disease was carefully collected in all patients. The intensity (according to VAS) and phenotype (Pain DETECT, DN4) of pain syndrome (PS), the presence of symptoms of central sensitization (CSI), fatigue (FSS), signs of anxiety and depression (HADS), sleep quality (PSQI), cognitive functions (DSST) and quality of life (QoL) (EQ-5D, FIQR) were also evaluated.</p><p><strong>Results: </strong>The average age of patients in the FM group was significantly lower (42 [35; 53] vs. 50 [42.5; 59], <i>p</i>=0.042). Patients with «pure» FM without RA were more often divorced and had no children (<i>p</i>=0.045 and <i>p</i>=0.02, respectively). The duration of PS in the groups did not differ (11 [7; 17] vs. 8 [5; 13] years, <i>p</i>=0.429), however, patients with «pure» FM waited longer for diagnosis (115 [40; 198] vs. 20 [5.5; 59] months, <i>p</i><0.001), and they also were less likely to be recognized as disabled (<i>p</i>=0.003). Patients of both groups had equally severe fatigue, anxiety, depression, sleep disorders and cognitive functions compared to the norms. Patients of the FM group noted a lower QoL (according to EQ-5D, <i>p</i>=0.041) then in RA+FM group, despite the comparable severity of FM and the intensity of the PS in both groups.</p><p><strong>Conclusion: </strong>FM in patients with RA develops at a later age compared to «pure» FM. The clinical picture of FM with and without RA does not differ in the main manifestations, however, the QoL of patients with «pure» FM is lower. Accounting for fibromyalgia in the treatment of rheumatoid diseases can significantly improve the QoL of patients.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 2","pages":"28-36"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140095236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Psychopharmacotherapy of mixed affective states in bipolar disorder].","authors":"D S Petelin, A G Smoleevskiy, B A Volel'","doi":"10.17116/jnevro2024124021103","DOIUrl":"10.17116/jnevro2024124021103","url":null,"abstract":"<p><p>On the example of a patient with a mixed affective episode within the framework of bipolar affective disorder, the clinical features of this psychopathological condition, the difficulties of diagnosis and selection of therapy in mixed states are presented. The use of the modern atypical antipsychotic ziprasidone in this category of patients is argued.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 2","pages":"103-108"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140095265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The relationship between immunological and psychopathological characteristics in patients with focal epilepsy depending on the profile of interhemispheric asymmetry].","authors":"V V Kalinin, A A Zemlyanaya, K Y Subbotin","doi":"10.17116/jnevro202412402137","DOIUrl":"10.17116/jnevro202412402137","url":null,"abstract":"<p><strong>Objective: </strong>To identify the possible influence of cellular immunity parameters and neurobiological variables (frequency of seizures of various semiotics and their severity) on comorbid psychopathological symptoms depending on the profile of interhemispheric asymmetry in patients with focal forms of epilepsy.</p><p><strong>Material and methods: </strong>The study included 92 patients with epilepsy (38 men, 54 women, mean age 38.7+8.45 years). Focal temporal lobe epilepsy was diagnosed in 36 patients, focal frontal lobe epilepsy in 16 patients, and temporal-frontal lobe epilepsy in 40 patients. For each type of seizure, severity was assessed according to the National Seizure Severity Scale (NHS3). The mental status of patients was assessed using the SCL-90 self-report questionnaire. The Annette scale was used to assess the profile of interhemispheric asymmetry. The number of different clusters of lymphocytes was studied, including the number of T-lymphocytes (CD3+), T-helpers (CD3+CD4+), T-cytotoxic (CD3+CD8+), T-NK (natural killers CD3+CD16+CD56+), B-lymphocytes (CD3-CD19+), as well as immunoregulatory index (CD4/CD8 ratio). In order to identify any possible relationships between neurobiological and immune variables, on the one hand, and the SCL-90 constructs, on the other hand, a separate correlation analysis of Spearman ranks within the left-handed group and the right-handed group was carried out.</p><p><strong>Results: </strong>We revealed the differences between groups of patients with epilepsy with right and left profiles of hemispheric asymmetry regarding the relationship between the frequency of seizures, their severity and accompanying psychopathological variables, on the one hand, and between immunity indices and psychopathological constructs, on the other hand. It has been established that neurobiological and immune variables in left-handers can determine the psychopathological structure of the comorbid mental disorder.</p><p><strong>Conclusion: </strong>Prediction of concomitant psychopathological syndromes in patients with epilepsy on the basis of clinical data and data on immunity is quite possible, but only in left-handed patients.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 2","pages":"37-44"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140095270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}